Pipeline Overview

Our Approach Has Created an Innovative Pipeline
in Targeted Radiopharmaceuticals

ProgramIndicationDiscoveryLead OptimizationDevelopment CandidateClinical imaging, IND enablingClinical Trials (Phase 1-3)
RYZ101
(225Ac DOTATATE)

 
RYZ101
(225Ac DOTATATE)

 
Glypican-3, GPC3
(Novel Peptide)

 
Program A
(Novel Small Molecule)
Multiple Solid Tumors

 
Program B
(Novel Peptide)
Multiple Solid Tumors

 
Program C
(Novel Peptide)
Multiple Solid Tumors

 
Program D
(Novel Peptide)
Multiple Solid Tumors

 
Other Programs
(Peptide/Small Molecules)
Multiple Solid Tumors

 
DrugIndicationStage
RYZ101
(225Ac DOTATATE)
 Neuroendocrine TumorsClinical Trials (Phase 1-3)
RYZ101
(225Ac DOTATATE)
 Small Cell Lung CancerClinical Trials (Phase 1-3)
Glypican-3, GPC3
(Novel Peptide)
 Liver CancerClinical imaging, IND enabling
Program A
(Novel Small Molecule)
 Multiple Solid TumorsClinical imaging, IND enabling
Program B
(Novel Peptide)
 Multiple Solid TumorsClinical imaging, IND enabling
Program C
(Novel Peptide)
 Multiple Solid TumorsLead Optimization
Program D
(Novel Peptide)
 Multiple Solid TumorsDiscovery
Other Programs
(Peptide/Small Molecules)
 Multiple Solid TumorsDiscovery